03:05 , Jun 30, 2018 |  BioCentury  |  Finance

Hidden in the rough

Judicious stock picking was especially important in the second quarter, as 57% of global biotech stocks saw their equity values decline. Volatility continued to roil global markets during the period and additional uncertainty looms with...
22:36 , Feb 9, 2018 |  BioCentury  |  Finance

Elites always welcome

The fact that 69 biotechs have raised $6.1 billion via IPO financings on NASDAQ since the start of 2016 might suggest the IPO window has remained wide open in the U.S. A closer look at...
07:00 , Apr 4, 2016 |  BioCentury  |  Finance

Frazier's GAIN

The benefits of the Generating Antibiotic Incentives Now Act, coupled with the ability to back repeat entrepreneurs, prompted Frazier Healthcare Partners to lead investments in two series A rounds for antibiotics companies in the span...
07:00 , Oct 13, 2014 |  BC Week In Review  |  Company News

Neurocrine management update

Neurocrine Biosciences Inc. (NASDAQ:NBIX), San Diego, Calif.   Business: Neurology, Cardiovascular, Genitourinary   Hired: Malcolm Lloyd-Smith as chief regulatory officer, formerly SVP of regulatory affairs, quality and clinical at Cadence Pharmaceuticals Inc. , which Mallinckrodt...
07:00 , Mar 24, 2014 |  BC Week In Review  |  Company News

Cadence, Mallinckrodt deal

Specialty pharma Mallinckrodt completed its acquisition of Cadence for $14 per share in cash, or about $1.3 billion (see BioCentury, Feb. 17). Cadence Pharmaceuticals Inc. , San Diego, Calif.   Mallinckrodt plc (NYSE:MNK), St. Louis,...
07:00 , Mar 24, 2014 |  BioCentury  |  Finance

Horizon's Irish jig

Horizon Pharma Inc. (NASDAQ:HZNP) thinks Vidara Therapeutics International Ltd. 's lone drug, Actimmune interferon gamma-1b, by itself justifies the $660 million price tag for last week's acquisition. Thus, Horizon expects it is getting the tax...
08:00 , Feb 17, 2014 |  BC Week In Review  |  Company News

Cadence, Mallinckrodt deal

Specialty pharma Mallinckrodt will acquire Cadence for $14 per share in cash, or about $1.3 billion on a fully diluted basis. The price is a 26% premium to Cadence's close of $11.07 on Feb. 10,...
08:00 , Feb 17, 2014 |  BioCentury  |  Finance

Highlights of weekly biotech stock moves

Regulatory milestones Cubist Pharmaceuticals Inc. (NASDAQ:CBST) was up $0.73 to $73.55 last week after FDA's Anti-Infective Drugs Advisory Committee said it will meet on March 31 to discuss a pair of NDAs covering IV and...
01:58 , Feb 12, 2014 |  BC Extra  |  Top Story

Mallinckrodt to acquire Cadence

Specialty pharma Mallinckrodt plc (NYSE:MNK) gained $6.88 (12%) to $66.19 on Tuesday after announcing it will acquire Cadence Pharmaceuticals Inc. (NASDAQ:CADX) for $14 per share in cash, or about $1.3 billion on a fully diluted...
08:00 , Nov 18, 2013 |  BC Week In Review  |  Company News

Cadence, Exela Pharma Sciences LLC neurology news

The U.S. District Court for the District of Delaware ruled in favor of Cadence in a patent infringement suit against Exela regarding Cadence's Ofirmev acetaminophen injection for pain and fever. In 2011, Cadence filed Cadence...